Virpax Pharmaceuticals, Inc. filed its 10-K on Mar 22, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | +19.22% | +31.60% | -5.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.03% | 2.99M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- VRPX Stock
- News Virpax Pharmaceuticals, Inc.
- Virpax Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt